SCHEMBL14027348

SCHEMBL14027348

CC(C)(C)NCC(O)C(C)(C)C

nearest known ligand 0.62

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.46
LMNA P02545 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CASP7 P55210 1/20 0.42
KMT2A Q03164 1/20 0.42
HIF1A Q16665 1/20 0.42
ADRB2 P07550 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11340223 0.79 ADRB2 (0.40) TSHRLMNACYP3A4CYP2C9CASP7
SCHEMBL20228194 0.79 LMNA (0.39) TSHRLMNACYP3A4CYP2C9CASP7
SCHEMBL10245376 0.79 PKM (0.48) TSHRLMNACYP3A4CYP2C9CASP7
SCHEMBL20746800 0.79 TSHR (0.42) TSHR
SCHEMBL22721124 0.77
SCHEMBL7063746 0.77 CYP2D6 (0.48)
SCHEMBL21115026 0.76 LMNA (0.41) TSHRLMNACYP3A4CYP2C9CASP7
SCHEMBL756930 0.74
SCHEMBL437044 0.74
SCHEMBL12967296 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226225-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. (US) 2024-07-11 US disclosed
EP-2710018-B1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2021-12-29 EP disclosed
US-20200131285-A1 NOVEL POLYMERS AND DNA COPOLYMER COATINGS ILLUMINA CAMBRIDGE LIMITED (GB) 2020-04-30 US disclosed
US-10577439-B2 Polymers and DNA copolymer coatings ILLUMINA CAMBRIDGE LIMITED (GB) 2020-03-03 US disclosed
US-20190194363-A1 NOVEL POLYMERS AND DNA COPOLYMER COATINGS ILLUMINA CAMBRIDGE LIMITED (GB) 2019-06-27 US disclosed
US-20180155469-A1 NOVEL POLYMERS AND DNA COPOLYMER COATINGS ILLUMINA CAMBRIDGE LIMITED (GB) 2018-06-07 US disclosed
US-9815916-B2 Polymers and DNA copolymer coatings ILLUMINA CAMBRIDGE LIMITED (GB) 2017-11-14 US disclosed
US-9815916-B2 Polymers and DNA copolymer coatings ILLUMINA CAMBRIDGE LIMITED (GB) 2017-11-14 US disclosed
US-9714464-B2 Precursors for atomic layer deposition WAYNE STATE UNIVERSITY (US) 2017-07-25 US disclosed
US-20160122816-A1 NOVEL POLYMERS AND DNA COPOLYMER COATINGS ILLUMINA CAMBRIDGE LIMITED (GB) 2016-05-05 US disclosed
US-20150159273-A1 Precursors for Atomic Layer Deposition NATIONAL SCIENCE FOUNDATION 2015-06-11 US disclosed
US-20080262226-A1 METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR ARTESIAN THERAPEUTICS, INC. (CA) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150159273-A1 Precursors for Atomic Layer Deposition ADH1A, ADH1C, AKR7A2 TSHR 4391/4885LMNA 46/4885CYP3A4 321/4885
US-20080262226-A1 METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR AND A LINKER AND METHODS OF MAKING COMPOUNDS HAVING A BETA-ADRENERGIC INHIBITOR, A LINKER AND A PHOSPHODIESTERASE INHIBITOR ADRB2, ADRB3, ADRB1 TSHR 971/4885LMNA 976/4885CYP3A4 686/4885
US-20240226225-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, SLC40A1, FTH1 TSHR 1076/4885LMNA 635/4885CYP3A4 4559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.